Zhongsheng Pharmaceutical Co., Ltd. raised 200 million yuan for the cooperative R & D project of small molecule chemical innovative drugs in Xianqiang Pharmaceutical Co., Ltd

Zhongsheng pharmaceutical announced on November 10 that it plans to increase no more than 88.0282 million shares per share by no less than 11.36 yuan, and raise about 1 billion yuan, which is mainly used to pay the purchase price of phase II to phase IV of Xianqiang pharmaceutical equity and the cooperative R & D project of "class 1.1 small molecule chemical innovative drugs", while the rest will supplement the working capital Of the 1 billion yuan raised, 600 million yuan is intended to be used to pay the purchase price of phase II to phase IV of Xianqiang pharmaceutical Xianqiang pharmaceutical is mainly engaged in the development of antiviral, antibiotic, obstetric, cardiovascular and cerebrovascular chemicals and APIs On March 22 this year, Zhongsheng pharmaceutical announced that it would purchase 97.69% equity of Xianqiang pharmaceutical with cash of 1.27 billion yuan According to the relevant commitments issued by the counterparties at that time, the net profit of Xianqiang pharmaceutical from 2015 to 2017 after deducting non profits should reach 80 million yuan, 96 million yuan and 115 million yuan respectively Another 200 million yuan will be raised for the cooperative R & D project of "class 1.1 small molecule chemical innovative drugs" The project focuses on the advantages of Ophthalmology, oncology, cardio cerebrovascular and diabetes The partner, Wuxi apptec, is a world-famous and leading company in new drug research and development, biotechnology and medical device research and development, with 13 operating entities in China and the United States In September 2013 and March 2014, the company and Wuxi apptec signed technical cooperation agreements on "R & D of new zsym001, a new drug for the treatment of ischemic cerebrovascular diseases", and "R & D of new zsym002, a new drug for the treatment of tumors" At present, both projects are progressing smoothly and have achieved phased results as planned, among which zsym002 project has entered the stage of safety evaluation research In August and September of this year, the two sides signed two technical development (cooperation) contracts, namely, "R & D of zsym003, a new drug for drug-resistant lung cancer", and "R & D of zsym004, a new drug for tumor treatment" Guangdong Zhongsheng Pharmaceutical Co., Ltd Guangdong Zhongsheng Pharmaceutical Co., Ltd is a high-tech enterprise dedicated to human health products The company was founded in 1979 with a registered capital of 60 million yuan Its main business involves drug research and development, production and sales With the support of governments at all levels and all sectors of society, the company's business has developed rapidly and its comprehensive strength has been continuously improved It has been rated as an excellent high-tech enterprise in Guangdong Province, a key high-tech enterprise in the national torch plan, and a AAA + quality credit enterprise in China, and has won more than 30 honorary awards at the national, provincial and municipal levels The company's "Zhongsheng brand" trademark was rated as a famous trademark in Guangdong Province, and the company's "compound shuantong capsule" and "Zhongsheng pill" were rated as famous brand products in Guangdong Province Guangdong Zhongsheng Pharmaceutical Co., Ltd has always been adhering to the enterprise tenet of "caring for life with high-quality products and healthy public with high-quality products", committed to research and development, manufacturing high-quality products, and expanding the market with passion, striving to provide customers with accurate and professional services In terms of research and development, the company pays attention to the prevention and treatment of cardiovascular and cerebrovascular diseases, diabetes and its chronic complications, eye diseases and degenerative nervous system diseases, and strives to develop corresponding drugs with high-tech content and independent intellectual property rights In terms of production, through strict GMP management, standardized production and operation system and leading fingerprint quality control technology, we can provide patients with drugs with stable quality and excellent quality In terms of marketing, medical professionals provide professional services for patients, doctors and business partners, and create a high-quality and healthy brand image of Zhongsheng pharmaceutical industry through various OTC promotion activities Guangdong Xianqiang Pharmaceutical Co., Ltd Guangdong Xianqiang Pharmaceutical Co., Ltd was changed from a limited company to a joint stock company in January 2013 The company is located in the high-tech industrial park of Conghua Economic Development Zone, Guangdong Province It was founded in 2002 It is mainly engaged in the research, production and sales of chemical pharmaceutical preparations, APIs, biochemical and biological drugs It is recognized as a national high-tech enterprise, a high growth private enterprise in Guangdong Province, a private science and technology enterprise in Guangzhou, a Class-A taxpayer of tax credit rating in Guangzhou It is Conghua City, Guangzhou City and Guangzhou city Small and medium-sized enterprises supported by the third level government of the eastern province Xianqiang pharmaceutical plant covers an area of about 38 mu At present, it has eight dosage forms and eleven production lines, including API, sub packaged powder injection, freeze-dried powder injection, cephalosporin powder injection, tablet, capsule, granule and small volume injection, all of which have passed the national GMP certification By the end of 2012, a total of 45 drug production numbers had been obtained, including antibacterial drugs, antiviral drugs, cardio cerebrovascular drugs, Hepatology drugs, obstetrics and Gynecology drugs, hemostatic drugs and nutritional supplements The main products include: cefixime dispersible tablets, adenosine monophosphate for injection, etc